Animalcare: in the recovery room or more surgery needed?
This animal health business appeared to have a bright future when we covered it in an earlier research commentary. Unfortunately, the merger with an ambitious European animal healthcare business resulted in a host of problems and a material decline in the share price. With a new chief executive at the helm the future is thankfully looking brighter.
The sale of vaccines, medicines and medical devices for companion animals alone is a massive business, exceeding $8bn annually in 2018 with an additional $14bn in sales of vaccines and medicines for livestock. The sector is dominated by US listed Zoetis Inc, which was spun out of pharmaceutical giant Pfizer in 2012. Zoetis, which has a current market capitalisation of $60bn, has seen its share price rise threefold since its IPO and now trades at a heady 35 times current year estimates.
The September 2018 IPO of Elanco Animal Health Inc, a former subsidiary of Eli Lilly, also highlighted the appeal of the…
Continue reading this article…
- In depth coverage of many of the world’s great companies
- Breaking news on potential upcoming disasters
- Unique insights from our top research team
- Only pay for what you want to read
- Easy credit payment system
- Access our excellent Premium content
This article was written by experts from Fundamental Asset Management.
Specialist Inheritance Tax (IHT) investment management firm, Fundamental, has unrivalled knowledge of AIM and smaller quoted companies. Fundamental has successfully managed AIM portfolios for IHT planning purposes since 2004, delivering outstanding growth for its clients, well ahead of mainstream funds and stock market indices.
Find out more about Fundamental’s services.
Previous article Next article